Conference Coverage

ASCO 2014: LIVE COVERAGE

HPV-Targeted Adoptive T-cell Therapy Induces Regression in Metastatic Cervical Cancer

HPV-Targeted Adoptive T-cell Therapy Induces Regression in Metastatic Cervical Cancer

CHICAGO, IL—Durable, complete tumor regression can occur following a single infusion of human papillomavirus tumor-infiltrating lymphocytes in women with metastatic cervical cancer.

Ibrutinib 'Effective New Single-agent Therapy' for Relapsed/Refractory CLL

Ibrutinib 'Effective New Single-agent Therapy' for Relapsed/Refractory CLL

CHICAGO, IL—Ibrutinib significantly improved progression-free survival, overall survival, and overall response rate when compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Biomarkers Fail to Predict Platinum Chemo Response in TNBC

Biomarkers Fail to Predict Platinum Chemo Response in TNBC

CHICAGO, IL—Established biomarkers failed to predict response to platinum in patients with metastatic triple-negative breast cancer.

Discontinuing Statins OK for Terminal Patients

Discontinuing Statins OK for Terminal Patients

CHICAGO, IL— Discontinuation of statin therapy does not shorten survival and improves quality of life among patients with a life expectancy of less than 1 year.

Afatinib + Paclitaxel Effective in EGFR Inhibitor-resistant Lung Cancer

Afatinib + Paclitaxel Effective in EGFR Inhibitor-resistant Lung Cancer

CHICAGO, IL— Non-small cell lung cancer tumors that progress on the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib/gefitinib and afatinib continue to depend on ErbB family receptor signaling.

Early Palliative Support for Family Caregivers Reduces Depression

Early Palliative Support for Family Caregivers Reduces Depression

CHICAGO, IL— Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.

Nivolumab + Ipilimumab: 'Unprecedented' Survival Rates in Advanced Melanoma

Nivolumab + Ipilimumab: 'Unprecedented' Survival Rates in Advanced Melanoma

CHICAGO, IL—Concurrent treatment with nivolumab plus ipilimumab resulted in "unprecedented" 2-year rates of overall survival in patients with advanced melanoma regardless of BRAF-mutation status.

Ramucirumab + Docetaxel Improves Survival in Stage IV NSCLC

Ramucirumab + Docetaxel Improves Survival in Stage IV NSCLC

CHICAGO, IL—Second-line ramucirumab plus docetaxel significantly improved overall survival, progression-free survival and overall response rates compared with docetaxel alone in patients with stage IV non-small cell lung cancer.

Genotype-directed Afatinib Ups Overall Survival in Some Lung Cancers

Genotype-directed Afatinib Ups Overall Survival in Some Lung Cancers

CHICAGO, IL— First-line afatinib is associated with prolonged survival in treatment-naïve patients with advanced non-small cell lung cancers that harbor Del19-mutant epidermal growth factor receptor.

Onartuzumab: No Survival Benefits in Advanced Lung Cancer

Onartuzumab: No Survival Benefits in Advanced Lung Cancer

CHICAGO, IL— Adding onartuzumab to erlotinib in previously treated advanced, MET-positive non-small cell lung cancer (NSCLC) did not improve patient survival.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs